Long-term efficacy, safety, and tolerability of a subcutaneous immunoglobulin 16.5% (cutaquig®) in the treatment of patients with primary immunodeficiencies.
Clin Exp Immunol
; 210(2): 91-103, 2022 12 15.
Article
in En
| MEDLINE
| ID: mdl-36208448
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Bacterial Infections
/
Immunologic Deficiency Syndromes
Type of study:
Observational_studies
/
Risk_factors_studies
Limits:
Humans
Language:
En
Journal:
Clin Exp Immunol
Year:
2022
Document type:
Article
Affiliation country:
United States
Country of publication:
United kingdom